Cite
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
MLA
Ribera, E., et al. “Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Lipoatrophy: The RECOMB Study Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Lipoatrophy: The RECOMB Study.” HIV Medicine, vol. 14, no. 6, July 2013, pp. 327–36. EBSCOhost, https://doi.org/10.1111/hiv.12011.
APA
Ribera, E., Larrousse, M., Curran, A., Negredo, E., Clotet, B., Estrada, V., Sanz, J., Berenguer, J., Rubio, R., Pulido, F., Ferrer, P., Alvarez, M., Arterburn, S., & Martínez, E. (2013). Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. HIV Medicine, 14(6), 327–336. https://doi.org/10.1111/hiv.12011
Chicago
Ribera, E, M Larrousse, A Curran, E Negredo, B Clotet, V Estrada, J Sanz, et al. 2013. “Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Lipoatrophy: The RECOMB Study Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Lipoatrophy: The RECOMB Study.” HIV Medicine 14 (6): 327–36. doi:10.1111/hiv.12011.